FATE Q3 2024 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+58.1% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$52M-1703.9% margin

Net Income

-$48M-1551.0% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-54.6%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$495M

Total Liabilities

$133M

Stockholders' Equity

$362M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+58.1%
Gross Profit	$3M	-$3M	+209.9%
Operating Income	-$52M	-$51M	-2.1%
Net Income	-$48M	-$45M	-5.6%